GlaxoSmithKline PLC will have a promising new money-spinner to crow about on Oct 25 when it reports third-quarter results after the FDA approved its highly efficient shingles vaccine Shingrix, which analysts expect to become a blockbuster.
The vaccine's approval covers people 50 years or older, as a prevention tool against the painful, blistering rash. Shingles is the result of reactivation of the varicella-zoster virus, which causes...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?